MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%
ALLO — Allogene Therapeutics, Inc. Common Stock
NasdaqAllogene Therapeutics, Inc. Common Stock
$1.54
-0.06(-3.75%)
- O
- 1.60
- H
- 1.61
- L
- 1.53
- V
- 4.57M
⏱️ End-of-day dataAs of Oct 1, 2026
Chart
About ALLO
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateOct 11, 2018
Employees152
Stock ExchangeNasdaq
Ticker SymbolALLO
Websitehttps://www.allogene.com
Key Financial Statistics
| Market Cap | $570.06M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $0.86 - $55.00 |
| 52-Week Avg Volume | 2.37M |
| VWAP | $1.58 |
| Transactions | 11,364 |
| Total Recorded Bars | 2,003 days |